Results 121 to 130 of about 6,214,933 (159)

Management Strategies for CLN2 Disease [PDF]

open access: yesPediatric Neurology, 2017
CLN2 disease (neuronal ceroid lipofuscinosis type 2) is a rare, autosomal recessive, pediatric-onset, rapidly progressive neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 (TPP1) enzyme deficiency, and is characterized by language delay, seizures, rapid cognitive and motor decline, blindness, and early death.
Boris Zernikow   +2 more
exaly   +6 more sources

Managing CLN2 Disease: A Treatable Neurodegenerative Condition Among Other Treatable Early Childhood Epilepsies [PDF]

open access: yesExpert Review of Neurotherapeutics, 2021
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric neurodegenerative condition, which is usually fatal by mid-adolescence. Seizures are one of the most common early symptoms of CLN2 disease, but patients often experience language deficits, movement disorders, and behavioral problems.
Igor Prpić   +2 more
exaly   +5 more sources

MRI in CLN2 Disease Patients: Subtle Features That Support an Early Diagnosis [PDF]

open access: yesEuropean Journal of Paediatric Neurology, 2020
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, paediatric-onset, neurodegenerative disorder characterised in its early stages by language delay, seizures and loss of motor function. It is rapidly progressive and ultimately results in the premature death of patients.
Cengiz Havalı   +2 more
exaly   +8 more sources

Study of Intraventricular Cerliponase Alfa for CLN2 Disease [PDF]

open access: yesNew England Journal of Medicine, 2018
Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of ...
Jonathan P. Dyke   +2 more
exaly   +6 more sources

A Novel Porcine Model of CLN2 Batten Disease That Recapitulates Patient Phenotypes

open access: yesNeurotherapeutics, 2022
CLN2 Batten disease is a lysosomal disorder in which pathogenic variants in CLN2 lead to reduced activity in the enzyme tripeptidyl peptidase 1. The disease typically manifests around 2 to 4 years of age with developmental delay, ataxia, seizures, inability to speak and walk, and fatality between 6 and 12 years of age.
Jill M Weimer
exaly   +3 more sources

Cerliponase Alfa for CLN2 Disease, a Promising Therapy

Expert Opinion on Orphan Drugs, 2020
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare, lysosomal storage disease that causes progressive neurodegeneration in children.
Nicolas J Abreu, Jonathan Pindrik
exaly   +2 more sources

Speech, Language and Non-Verbal Communication in CLN2 and CLN3 Batten Disease

open access: yesJournal of Inherited Metabolic Disease
CLN2 and CLN3 diseases, the most common types of Batten disease (also known as neuronal ceroid lipofuscinosis), are childhood dementias associated with progressive loss of speech, language and feeding skills.
Ruth O Braden   +2 more
exaly   +2 more sources

Gene therapy for CLN2 disease

Science, 2020
Gene Therapy Late infantile Batten disease (CLN2 disease), a pediatric progressive brain disorder, is currently treated by infusion of human recombinant tripeptidyl peptidase 1 (TPP1) into the cerebrospinal fluid every other week, which slows but does not halt progression of the disease. Sondhi et al. sought an alternative treatment using gene therapy.
openaire   +1 more source

Mitochondrial abnormalities in CLN2 and CLN3 forms of batten disease

Molecular and Chemical Neuropathology, 1996
The storage of subunit c of mitochondrial ATP synthase, other hydrophobic peptides, and autofluorescent pigment in both late infantile (CLN2) and juvenile (CLN3) neuronal ceroid lipofuscinosis, but not in infantile (CLN1), has raised the question of abnormal mitochondrial function.
G, Dawson   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy